Page last updated: 2024-12-05

2,6-xylidine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

2,6-xylidine: RN given refers to parent cpd [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

2,6-dimethylaniline : A primary arylamine that is aniline in which the hydrogens at the 2- and 6-positions are replaced by methyl groups. It is used in the production of some anasthetics and other chemicals. It is a drug metabolite of lidocaine (local anasthetic). [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID6896
CHEMBL ID1340793
CHEBI ID28738
SCHEMBL ID106244
MeSH IDM0051145

Synonyms (94)

Synonym
vic-m-xylidine
CHEBI:28738 ,
aniline,6-dimethyl-
nsc-7098
nci-c56188
nsc7098
2-amino-m-xylene
benzenamine,6-dimethyl-
wln: zr b1 f1
2-amino-1,3-xylene
o-xylidine
2-amino-1,3-dimethylbenzene
1-amino-2,6-dimethylbenzene
2,6-dimethylbenzenamine
ccris 2373
benzene, 2-amino-1,3-dimethyl-
2,6-dimethylphenylamine
2,6-xylylamine
brn 0636332
einecs 201-758-7
ai3-52358
nsc 7098
aniline, 2,6-dimethyl-
o-xylidine (van)
hsdb 2094
benzenamine, 2,6-dimethyl-
inchi=1/c8h11n/c1-6-4-3-5-7(2)8(6)9/h3-5h,9h2,1-2h
NCGC00091576-01
2,6-dimethylaniline
2,6-dma
2,6-xylidine
87-62-7
2,6-dimethylaniline, analytical standard
2,6-dimethylaniline, 99%
AC-11240
D0669
FT-0667311
AKOS000120115
A842302
NCGC00091576-03
NCGC00091576-02
tox21_300055
cas-87-62-7
tox21_201426
NCGC00254105-01
NCGC00258977-01
dtxsid8026307 ,
dtxcid006307
(2,6-dimethyl-phenyl)-amine
STL281861
unii-4ft62ox08d
4-12-00-02521 (beilstein handbook reference)
4ft62ox08d ,
ec 201-758-7
FT-0610696
PS-3428
AM20050570
2,6-xylidine [hsdb]
ropivacaine hydrochloride monohydrate impurity h [ep impurity]
lidocaine impurity a [ep impurity]
xylidine 2,6-dimethylbenzenamine
lidocaine hydrochloride impurity a [ep impurity]
2,6-dimethylaniline [usp impurity]
2,6-dimethylaniline [iarc]
xylidine 2,6-dimethylbenzenamine [mi]
xylazine hydrochloride impurity a [ep impurity]
mepivacaine hydrochloride impurity a [ep impurity]
bupivacaine hydrochloride impurity f [ep impurity]
xylidene, 2,6-
SCHEMBL106244
2,6 dimethyl aniline
2.6-dimethylaniline
2,6-dimethyl aniline
2,6-dimethyl-phenylamine
2,6 dimethylaniline
2,6-dimethylbenzeneamine
(2,6-dimethylphenyl)amine
2,6-dimethyl-aniline
CHEMBL1340793
STR00521
J-507530
F2190-0466
mfcd00007747
2,6-dimethylaniline, purum, >=98.0% (gc)
2,6-dimethylaniline, pestanal(r), analytical standard
bupivacaine impurity f, european pharmacopoeia (ep) reference standard
2,6-dimethylaniline 100 microg/ml in isooctane
1092805-08-7
2,6-dimethylaniline-d11
Z57127391
CS-0012942
Q4353533
EN300-17976
PD065540

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" The weight of evidence indicates 2,6-xylidine is a non-direct acting (metabolic threshold-dependent) genotoxin, and is not genotoxic in vivo in rats in the absence of acute systemic toxic effects, which occur at levels 35 × beyond lidocaine-related exposure in humans."( A weight of evidence assessment of the genotoxicity of 2,6-xylidine based on existing and new data, with relevance to safety of lidocaine exposure.
Johnson, GE; Kirkland, DJ; Sheil, ML; Streicker, MA, 2021
)
1.15

Pharmacokinetics

ExcerptReferenceRelevance
" In the current study, to evaluate the daily oral intake of aniline and 2,6-dimethylaniline in humans, forward and reverse dosimetry was carried out using simplified in silico physiologically based pharmacokinetic (PBPK) modeling established using in vivo experimental pharmacokinetic data."( Forward and reverse dosimetry for aniline and 2,6-dimethylaniline in humans extrapolated from humanized-liver mouse data using simplified physiologically based pharmacokinetic models.
Miura, T; Shimizu, M; Suemizu, H; Uehara, S; Yamazaki, H, 2022
)
0.72

Compound-Compound Interactions

ExcerptReferenceRelevance
" The proposed method was based on two-dimensional online solid phase extraction combined with liquid chromatography tandem mass spectrometry (SPE/LC-MS/MS)."( Rapid determination of six carcinogenic primary aromatic amines in mainstream cigarette smoke by two-dimensional online solid phase extraction combined with liquid chromatography tandem mass spectrometry.
Bie, Z; Chen, Y; Ji, L; Lu, W; Ren, H; Zhu, Y, 2017
)
0.46

Dosage Studied

ExcerptRelevanceReference
" In rats, repeated administration of either xylidine for 10 days failed to increase the appearance of metabolites, but 3-methylcholanthrene (3-MC) did increase the urinary concentration of AAMBA in 2,4-DMA dosed rats."( The in vivo oxidative metabolism of 2,4- and 2,6-dimethylaniline in the dog and rat.
Barker, SA; Hardy, ML; Short, CR, 1989
)
0.28
" The optimized methods show good linearity, precision (RSD < 2%) and accuracy (bias < 2% for dosage forms)."( Validation of high-performance liquid chromatographic methods on two silica base-deactivated reversed phases for the determination of chloroprocaine and bupivacaine.
Brun, F; Veuthey, JL, 1996
)
0.29
" Dose-response relationships were determined in the parental AA8 cell line, its repair-deficient UV5 subclone and other repair-deficient 5P3NAT2 or -proficient 5P3NAT2R9 subclones engineered to express mouse cytochrome P4501A2 (CYP1A2) and human N-acetyltransferase (NAT2), and also in AS52 cells harboring the bacterial guanine-hypoxanthine phosphoribosyltransferase (gpt) gene."( Genotoxicity of 2,6- and 3,5-dimethylaniline in cultured mammalian cells: the role of reactive oxygen species.
Belanger, CL; Chao, MW; Engelward, BP; Ge, J; Kim, MY; Skipper, PL; Tannenbaum, SR; Trudel, LJ; Wogan, GN; Ye, W, 2012
)
0.38
" The methods allowed local measurement of lidocaine in stratum corneum, punch biopsies, and plasma and of 2,6-DMA in plasma and biopsies obtained from minipigs dosed with experimental transdermal formulations."( Measurement of lidocaine and 2,6-dimethylaniline in minipig plasma, skin, and dermal tapes using UHPLC with electrospray MS/MS.
Bakhtiar, R; Engel, BJ; Green, C; King, B; Li, Q; Magers, T; Shoup, R, 2018
)
0.48
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (2)

RoleDescription
carcinogenic agentA role played by a chemical compound which is known to induce a process of carcinogenesis by corrupting normal cellular pathways, leading to the acquistion of tumoral capabilities.
drug metabolitenull
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (2)

ClassDescription
dimethylanilineA methylaniline carrying at least two methyl groups.
primary arylamineA primary amine formally derived from ammonia by replacing one hydrogen atom by an aryl group. R-NH2 where R is an aryl group.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (5)

PathwayProteinsCompounds
Lidocaine (Antiarrhythmic) Action Pathway4922
Lidocaine (Local Anaesthetic) Action Pathway3325
Lidocaine (Local Anaesthetic) Metabolism Pathway416
Lidocaine Pathway, Pharmacokinetics75
Lidocaine metabolism08

Protein Targets (3)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
retinoid X nuclear receptor alphaHomo sapiens (human)Potency11.42240.000817.505159.3239AID1159527
estrogen nuclear receptor alphaHomo sapiens (human)Potency54.16220.000229.305416,493.5996AID743075
peroxisome proliferator activated receptor gammaHomo sapiens (human)Potency38.34390.001019.414170.9645AID743094
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (2)

Assay IDTitleYearJournalArticle
AID1148535Genotoxicity in Salmonella typhimurium TA-1538 after 2 days by Ames test in presence of C57BL/6J mouse liver S9 fraction relative to control1978Journal of medicinal chemistry, Aug, Volume: 21, Issue:8
N-Hydroxyamide metabolites of lidocaine. Synthesis, characterization, quantitation, and mutagenic potential.
AID1148534Genotoxicity in Salmonella typhimurium TA-1538 after 2 days by Ames test relative to control1978Journal of medicinal chemistry, Aug, Volume: 21, Issue:8
N-Hydroxyamide metabolites of lidocaine. Synthesis, characterization, quantitation, and mutagenic potential.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (61)

TimeframeStudies, This Drug (%)All Drugs %
pre-19909 (14.75)18.7374
1990's8 (13.11)18.2507
2000's21 (34.43)29.6817
2010's17 (27.87)24.3611
2020's6 (9.84)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 52.00

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index52.00 (24.57)
Research Supply Index4.26 (2.92)
Research Growth Index4.73 (4.65)
Search Engine Demand Index80.74 (26.88)
Search Engine Supply Index1.99 (0.95)

This Compound (52.00)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews3 (4.29%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other67 (95.71%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]